FDA grants Priority Review to Amgen's tarlatamab application for advanced small cell lung cancer
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for...